Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Swedish AI Medical Technologies now receives approval to trial AI for determining actual melanoma thickness prior to surgery

Dermalyser support tool has already demonstrated 100% sensitivity and 93% specificity for detecting invasive melanomas  Stockholm, Sweden, October 22, 2024 – Swedish AI Medical Technologies has announced approval to commence a clinical trial aimed at further validating the performance of Dermalyser, its advanced AI-driven diagnostic support tool for assessing melanoma. The primary goal of this investor-led, single-center, non-randomized, parallel, double-blinded, prospective clinical investigation is to evaluate Dermalyser’s ability to accurately determine melanoma thickness using

Finland ranks 4th in Europe for academic patents per capita

A new report published by the European Patent Office (EPO) today finds that patent applications for inventions originating in European universities have been on the rise over the past two decades, and now account for 10.2% of all patents filed at the EPO by European applicants. In Finland, academic patents represent 10% of all European patent applications filed by Finnish applicants at the EPO in the period 2000-2020.· Leading countries for academic patents are Germany, France, the UK and Italy · Finland ranks 11th as Finnish universities are responsible for 3.1% of all academic patents

Invitation to UPM’s webcast on Q3 2024 interim report

(UPM, Helsinki, 22 October 2024 at 10:00 EEST) – UPM will publish its interim report on Tuesday 29 October 2024 at 09:30–10:00 EET. After publication, the report will be available on the company website at www.upm.com . A webcast and a conference call for analysts and investors will start at 13:15 EET. The interim report will be presented in English by President and CEO Massimo Reynaudo and CFO Tapio Korpeinen. Participants can follow the webcast online via this link . Participants wishing to ask questions after

BioStock: Curasight well-placed in hot radiopharma sector

The radiopharmaceutical sector is gaining considerable momentum as companies increasingly recognize its potential to offer highly targeted cancer treatments. This has led to a surge in investments, acquisitions, and partnerships, positioning radiopharmacy as one of the hottest areas in oncology. Curasight, a Danish clinical-stage biotech company specializing in innovative precision radionuclide diagnostics and therapy, is well-placed to benefit from this growth.Read the full article at biostock.se: https://www.biostock.se/en/2024/10/curasight-well-placed-in-hot-radiopharma-sector/

BioStock has published an interview with CEO Sten R. Sörensen on IPF as the initial indication for CS014 and the Company’s strengthened focus on rare diseases

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for diseases with high unmet medical needs, today announced that BioStock has published an executive interview on the Company’s selection of rare disease Idiopathic Pulmonary Fibrosis (IPF) as the initial target indication for novel HDAC inhibitor CS014 and the strengthened Company focus on rare diseases.In the interview, Cereno’s CEO Sten R. Sörensen comments on IPF as new indication for CS014, what value Cereno Scientific can offer this patient group, the recent Capital Markets Day and

Dicot Pharma's results attract great attention in the US

Uppsala, Sweden, October 22, 2024. Dicot Pharma's in-depth clinical results from the company's phase 1 study have now been presented at the US's largest conference in sexual medicine. The results regarding the improved effect on erectile function that persisted for four weeks attracted great interest among experts as no other potency drug has ever shown similar results.At a conference in Arizona organized by the Sexual Medicine Society of North America (SMSNA) over the weekend, Dicot Pharma's in-depth results from the company's phase 1 study were presented for the first time. The results

Hemsö develops a nursing home in Essen for the Red Cross

Hemsö develops a new nursing home and a short-term assisted living facility with a lettable area of 6,000 square meters with 116 places in the city of Essen, in the state of North Rhine-Westphalia. A 20-year lease agreement has been signed with DRK-Kreisverband Essen e.V., a part of the German Red Cross. The investment amounts to EUR 22 million.DRK-Kreisverband Essen e.V. has been operating in Essen for over 135 years. Like most local associations within the German Red Cross, the association in Essen is both a national aid organization and an operator of social services such as care and

University hospitals in the UK join Homerton Healthcare's public cloud service from Sectra—enhances collaboration for improved care

Linköping, Sweden – October 22, 2024 – International medical imaging IT and cybersecurity company Sectra’s  (STO: SECT B) SaaS in the cloud, Sectra One Cloud, will be used by Barking, Havering and Redbridge University Hospitals NHS Trust (BHRUT) in the UK as they join Homerton Healthcare’s current cloud solution for medical imaging. By using one unified platform the current cooperation between the hospitals will be enhanced which is anticipated to improve workflow and production at lower cost. Moreover, it will relieve BHRUT’s IT burden and costs for IT as Sectra takes

InCoax and Tarana accelerate broadband deployment in Cleveland: 47 buildings and 502 apartments connected in just 45 days

InCoax Networks announces a successful collaboration with Tarana Wireless and DigitalC, leading to the rapid deployment of high-speed broadband in Cleveland, Ohio. This project showcases the potential of InCoax's MoCA Access technology to meet the growing demand for reliable, high-speed internet — without the cost or complexity of full fiber installations.Led by DigitalC, a non-profit technology social enterprise dedicated to closing the digital divide, the project sought to deliver affordable, high-speed internet to Cleveland, one of the least connected cities in the U.S. To accomplish

Valmet’s performance solution to optimize district heat production of Oulun Energia Oy in Finland

Valmet Oyj trade press release, October 22, 2024, at 9:30 a.m. EESTValmet is to deliver a Valmet DNA District Heating Manager solution for Oulun Energia’s district heating network in Oulu, Finland. The solution optimizes and controls the temperatures of heat supply across all production plants within the district heating network. It offers significant performance benefits by enhancing heat delivery efficiency, reducing heat losses, and improving the quality of district heating for end customers. The order is included in Valmet’s orders received of the third quarter 2024. The value of the

Semcon supports E.ON for more efficient project operations

Semcon has signed an agreement with E.ON Energiinfrastruktur to provide support in project governance and the implementation of the XLPM project methodology. The agreement, valid until 31 December 2025, ensures that E.ON Energiinfrastruktur will operate in line with XLPM to further strengthen and streamline their project operations.“We are pleased with the opportunity to collaborate with E.ON Energiinfrastruktur, a key player in the energy sector’s transition,” says Therése Hallberg from Semcon. “We can support their work towards a sustainable future by streamlining project processes and

BioStock: The temperature of Cereno Scientific after major news

Cereno Scientific has recently announced the selection of a rare disease, idiopathic pulmonary fibrosis, as the target indication for its second drug candidate, CS014. Along with the new data for its lead candidate, CS1, this marks a clear shift in strategy and focus: rare diseases that today leave patients without effective treatment options. CEO Sten R. Sörensen visited BioStocks studio to talk more about this.Watch the interview with CEO Sten R. Sörensen at biostock.se:https://www.biostock.se/en/2024/10/the-temperature-of-cereno-scientific-after-major-news/ This is a press release

Gasum and ABB deliver first of its kind energy market optimization solution

The new multi-market optimization solution offers customers comprehensive benefits by providing market flexibility and improving risk management. It includes full market access, trading and advisory services, and optimizing the use of assets.Nordic energy company Gasum and global technology leader ABB are bringing a new energy market optimization solution to energy intensive industry and utilities. The solution is offered by Gasum and powered by ABB Ability™ OPTIMAX®. The new multi-market optimization (MMO) solution offers customers comprehensive benefits in energy markets by ensuring

JM Interim Report January–September 2024

INCREASED SALES IN COMPETITION WITH LARGE SUPPLY ON EXISTING HOME MARKET· Revenue decreased to SEK 9,132m (10,444). · Operating profit decreased to SEK 424m (822). The operating margin decreased to 4.6 percent (7.9). · Profit before tax decreased to SEK 322m (746), and profit after tax decreased to SEK 191m (570). · Return on equity for the past twelve months amounted to 0.60 percent (13.5). · Earnings per share amounted to SEK 3.00 (8.90). · Consolidated cash flow including net investment in properties amounted to SEK 132m (–452). · The number of residential units sold

Kappahl Group expands its secondhand offering in Finnish and Swedish stores

In 2023, Kappahl Group began collecting and selling secondhand garments in its Swedish and Norwegian stores. Now, the company is taking the next step in its expansion by significantly increasing the number of Swedish stores offering secondhand clothing. Additionally, the concept is being launched in Kappahl's Finnish stores. Starting at the end of September and into early October, Kappahl introduced secondhand collections in ten stores across the Finnish market. Meanwhile, the number of Swedish stores offering secondhand products will expand from 16 to 35 throughout the fall. “

BioGaia AB: Interim Management Statement January – September 2024

THIRD QUARTER 2024(For balance sheet items, figures in parentheses refer to year-end 2023 figures. For income statement and cash flow items, they refer to the same period last year). Net sales amounted to SEK 304.0 million (317.7), a decrease of SEK 13.7 million, or 4% (excluding foreign exchange effects a decrease of 2%). Net sales in the Pediatrics segment amounted to SEK 225.8 million (255.8), a decrease of 12% (excluding foreign exchange effects a decrease of 9%). Net sales in the Adult Health segment amounted to SEK 76.6 million (59.2), an increase of 29% (excluding foreign

Faron’s Capital Markets Day 2024

Faron Pharmaceuticals Ltd.   (“Faron” or “the Company”)    Faron’s Capital Markets Day 2024 – BEXMAB follow-up data and update on drug development pipeline, partnering discussions and introducing new Scientific Advisory Board   Company Announcement, 22 October 2024   TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, will host a Capital Markets Day for investors, analysts and media today, Tuesday, 22 October 2024 at 08:00 am (EDT) / 13:00 pm (

Repurchases of shares during week 42, 2024

Between 14 October and 18 October 2024 Attendo AB (LEI code 549300KEJDL2FNITUW65) (“Attendo”) has repurchased in total 173,794 own shares (ISIN: SE0007666110) as part of the repurchase program initiated by the Board.The repurchases form part of the repurchase program of a maximum of 16,138,659 own shares for a total maximum amount of SEK 150,000,000 that Attendo announced on 19 July 2024. The repurchase program, which runs between 22 July 2024 and 24 October 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated Regulation (EU)

Q1 FY 2025 operating update and final sales results for Tenders 1 and 2 FY 2025

    22 October 2024  LSE: PDL     Petra Diamonds Limited (Petra or the Company)   Q1 FY 2025 operating update and final sales results for Tenders 1 and 2 FY 2025     Richard Duffy, Chief Executive Officer of Petra, commented:   “Following changes to the mine plans announced at our Investor Day, diamond production increased 7% from the previous quarter on the back of solid performances from Cullinan Mine and Williamson, with Finsch transitioning from continuous to a two-shift operation. We recorded 4 LTIs, resulting in our LTIFR rate

INVITATION: Finnair Q3 2024 result – Press conference / webcast and analyst webcast

Finnair Plc       Invitation          22 October 2024 at 09:00 a.m. EETFinnair will hold the Q3 2024 financial results press conference (in Finnish) on 29 October 2024 at 11:00 a.m. (Finnish time) its office at Tietotie 9 in Vantaa. It is also possible to participate in the press conference via a live webcast at https://finnairgroup.videosync.fi/2024-10-29-media. An English-language telephone conference and webcast will begin on 29 October 2024 at 1:00 p.m. (Finnish time). To access the conference, kindly first register at https://palvelu.flik.fi/teleconference/?id=50048503.After the

Interim report January - September 2024

High level of activity and good orders received   Quarter 3, 2024   · Orders received amounted to SEK 1,437m (1,488), equivalent to a currency neutral decline of 0.3 percent compared with the same period last year. · Net sales amounted to SEK 1,416m (1,574), equivalent to a currency neutral decline of 6.8 percent compared with the same period last year. · Adjusted EBITA was SEK 160.8m (175.4), giving an adjusted EBITA margin of 11.4 percent (11.1). · Operating profit amounted to SEK 129.0m (148.0), corresponding to an operating margin of 9.1 percent (9.4). · Net

SBB starts construction of new care home at Tenstaterrassen in Stockholm

Samhällsbyggnadsbolaget i Norden AB (“SBB”) is starting construction of a new nursing and care home at Tenstaterrassen in Stockholm, with construction scheduled to begin in the fourth quarter of 2024. The home will offer 80 beds spread over 8 wards and 6 floors. With its location next to Järvafältet, residents will have easy access to nature, recreation, and good transport links in the neighbourhood. “We look forward to contributing, together with the tenant Ersta diakoni, to new and much-needed housing for the elderly in Stockholm. Our joint ambition is to create a home-like environment

Q3 2024: Tangible improvement in operations

Important events during the third quarter · Net sales in Q3 amounted to SEK 143.7 m, corresponding to a decrease of 7.9% compared to last year (-5.1% adjusted for currency effects). · The EBITDA margin was 20.1%, corresponding to an increase of 2.0 %-points compared to last year. · Probi successfully implemented a new global ERP system, streamlining operations and enhancing efficiency across key business functions. · A new study suggests that consuming Probi's proprietary probiotic strain HEAL9[®] may serve as a potential therapeutic option for mitigating mild cognitive

There are no items matching the current filter
There are no more items matching the current filter
Back to top